-transparent.png){kind=logo}
The pharmacokinetic characteristics of iodamide, a contrast agent for excretion urography, were studied in seven normal subjects and in 15 patients with various degrees of renal impairment. Two different formulations were administered, namely, a 65% solution (iodamide 300) by slow intravenous injection and a 24% solution by slow intravenous (drip) infusion. Both preparations of iodamide exhibited characteristics of an open two-compartment model. In both normal subjects and patients, the contrast agent was excreted almost exlusively in urine. In normal subjects, the pharmacokinetic parameters of both formulations were similar, with a distribution half-life (1/2alpha) of about 3 minutes and a disposition half-life (t1/2beta) of about 69 minutes. An average of 84 per cent of the dose was excreted in urine within 4 hours after administration of iodamide with net renal tubular secretion of about 38 per cent. The binding of iodamide to plasma proteins was negligible, and the extent of biotransformation of iodamide was minimal. In patients with renal impairment, the disposition half-life (t1/2beta) of iodamide ranged from 4.1 to 16.4 hours. Other changes in pharmacokinetic parameters were also seen in patients with renal impairment.
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
January 1986,
British journal of clinical pharmacology,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
April 1991,
Journal of clinical pharmacology,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
March 2007,
Current medical research and opinion,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
January 2000,
Clinical pharmacology and therapeutics,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
May 2013,
European journal of clinical pharmacology,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
July 2013,
Clinical pharmacology in drug development,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
November 2014,
Clinical drug investigation,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
January 2007,
Clinical pharmacokinetics,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
January 1980,
The Journal of antimicrobial chemotherapy,
L T Difazio, and
S M Singhvi, and
A F Heald, and
D N McKinstry, and
S A Brosman, and
J Y Gillenwater, and
D A Willard
January 1979,
Chemotherapy,
